Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 250

Posts Tagged ‘Pharmaceutical industry’

Pharmaceutical Industry Invests in the Development of Early Clinical Research in Quebec

Posted by fidest press agency su mercoledì, 5 giugno 2019

During the 2019 BIO (Biotechnology Innovation Organization) International Convention (BIO 2019), CATALIS Québec announced that its eight pharmaceutical partners have renewed their financial commitments. Since its launch, GlaxoSmithKline, Pfizer, AbbVie, Takeda, Novartis, Merck, Servier and Roche have invested nearly CAD 1.6 million in the CATALIS initiative to support Quebec’s role as a global leader in the field of early clinical research.
Since 2017, this innovative public-private partnership has rallied some fifteen organizations working jointly to develop and establish clinical research global best practices for the benefit of patients and the public in Quebec.“To ensure our life sciences industry enjoys a solid reputation and a competitive edge, it is critical to attract more private investment. By mobilizing all actors of this sector of the economy, the CATALIS initiative strengthens Québec’s position as a leader in early-stage clinical research. The government is proud to support this project, which clearly shows the industry’s innovative character,” stated Pierre Fitzgibbon, Minister of Economy and Innovation.In addition to developing resources for the entire clinical research ecosystem in Quebec, the CATALIS initiative supports five institutions in the Quebec health care system: the Centre hospitalier de l’Université de Montréal (CHUM), the McGill University Health Centre (MUHC), the Centre hospitalier universitaire Sainte-Justine, the CHU de Québec – Université Laval and the Centre de Recherche du Centre hospitalier universitaire de Sherbrooke (CRCHUS). These partner institutions have received funding to support them as they implement their expertise in early clinical research, notably allowing them to hire highly qualified research staff.Early-stage clinical trials (phases 1 and 2) are the first studies conducted on humans to provide scientific proof of the safety and efficacy of a medication or some other therapeutic approach. These trials, which involve a small group of patients, often represent an opportunity to find a potential treatment for patients with serious diseases when standard therapies have failed.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Italy’s Pharmaceutical Industry Value Will Drop to $18.6 Billion by 2020 due to Struggling Economy, says GlobalData

Posted by fidest press agency su giovedì, 28 aprile 2016

eurozonaLONDON, UK (GlobalData) The pharmaceutical industry in Italy is set to decline from $21.3 billion in 2016 to $18.6 billion by 2020, at a negative compound annual growth rate of 3.3%, primarily due to the country’s struggling economy, according to research and consulting firm GlobalData. The company’s latest report states that the strict pricing of drugs through negotiations and external and internal reference pricing is a barrier to the launch of innovative molecules, and that sales of generics and over-the-counter drugs will increase over the forecast period.Adam Dion, MSc, GlobalData’s Senior Industry Analyst, explains: “The pharmaceutical industry in Italy will face a number of challenges over the next few years. An increase in the Italian government’s debt relative to GDP, and the country’s poor growth record, will decrease cash flow in the country, meaning the industry will stagnate.”
The Italian economy is also vulnerable to fluctuations in the demand and supply of goods and services in other countries. The Eurozone crisis is likely to result in lower demand for Italian products from other European countries, reducing exports and engendering a hostile environment for innovation or investment. India and China also present a threat as they have an edge in the generics market, and may usurp sales away from Italy’s domestic pharmaceutical space. Dion concludes: “Despite the tough economic environment faced by those operating within the Italian pharmaceutical industry, GlobalData believes there will be a number of opportunities to counteract declining sales, including efficient patent policies, E-Health programs, and government reforms to reduce public debt. Indeed, more companies will be interested in research and development after the Italian Patent and Trademark Office has created efficient patent policies to protect them.”

Posted in Cronaca/News, Estero/world news, Spazio aperto/open space | Contrassegnato da tag: , , | Leave a Comment »

Pharma IQ Publishes Big Pharma Global Recession Report

Posted by fidest press agency su sabato, 11 febbraio 2012

London. Industry wide economic climate study reveals bleak outlook for Pharmaceutical Industry in new report from Pharma-IQ.comIn the wake of high profile staff cuts at multinational global pharmaceutical and biotech companies, leading industry network Pharma IQ conducted a large scale study into job stability and future prospects for the industry in 2012.The results of the study have now been published in a 13 page special report entitled “Big Pharma Global Recession Report”.Among the finding of the study which surveyed hundreds of professionals is the fact that 44.4% of those surveyed are concerned their role being made redundant in the next twelve months.It was also revealed that the US and Europe are the two regions identified by the survey respondents as being hit harder specifically with regards to the pharmaceutical industry by the global economic crisis.The report however concludes that the Asian pharmaceutical market appears to be the least affected region by the global economic crisis with only 7.3 percent of survey participants identifying it as the region that had been hit the hardest.”With the growth in the pharmaceutical market in Asia and increasing demands of regulatory authorities for ethnic-specific data, we can definitely expect an increase in early stage clinical research conducted in Asia. More countries in the region will jump on the bandwagon, to position themselves to attract more early stage clinical trials into their countries,” said Dr. Melvin Toh, VP of Pharmaceutical Development, CK Life Sciences International.Other outcomes from the report include increasing outsourcing and offshoring, renewed scrutiny on sales ROI and net reaction in R&D spend.”All companies must remain profitable to survive and the pharmaceutical industry is no different. As economic landscapes change, pharmaceutical companies must find new models for growth and profitability in 2012 and beyond,” said Andrea Charles, Editor, Pharma IQ.The full report can be viewed exclusively at

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »